Bristol-Myers Squibb Company and Otsuka Pharmaceutical announced that the FDA approved the supplemental New Drug Application for Abilify (aripiprazole) as adjunctive, or add-on, treatment to antidepressant therapy in adults with major depressive disorder (MDD).